rocuronium bromide · Fresenius Kabi Usa · NDA 217472, 219108
Rocuronium Bromide
Earliest generic entry, as listed · earliest of 3 marketed strengths
22 Jul 2039
2 of 3 marketed strengths have no unexpired patent or exclusivity listed.
Blocked by patent: US 11998605.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11998605 | drug product · sets the listed date | 22 Jul 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217472 · 001 · RLD | solution, intravenous | 50MG/5ML (10MG/ML) | open |
| 217472 · 002 · RLD | solution, intravenous | 100MG/10ML (10MG/ML) | open |
| 219108 · 001 · RLD | solution, intravenous | 50MG/5ML (10MG/ML) | 22 Jul 2039 |